Suhrbier Andreas
Cooperative Research Center for Vaccine Technology, Queensland Institute of Medical Research, University of Queensland, Australia.
Expert Rev Vaccines. 2002 Aug;1(2):207-13. doi: 10.1586/14760584.1.2.207.
Vaccines against a number of diseases, including HIV, Epstein Barr virus, malaria and several cancers, are believed to require the coinduction of multiple alphabeta CD8+ cytotoxic T-lymphocyte responses that are directed towards a number of different target antigens. The difficulties associated with making large recombinant vaccines that contain numerous antigens has led to the development of alphabeta CD8+ cytotoxic T-lymphocyte polyepitope or polytope vaccine approach, where multiple (usually 8-10 amino acids long) alphabeta CD8+ cytotoxic T-lymphocyte epitopes, derived from several antigens are conjoined into single artificial constructs. Such polytope constructs can be delivered using a number of different vaccine vector modalities with each epitope in the construct emerging as individually immunogenic.
人们认为,针对包括艾滋病毒、爱泼斯坦-巴尔病毒、疟疾和几种癌症在内的多种疾病的疫苗,需要共同诱导针对多种不同靶抗原的多个αβ CD8+ 细胞毒性T淋巴细胞反应。制备含有多种抗原的大型重组疫苗存在困难,这促使了αβ CD8+ 细胞毒性T淋巴细胞多表位或多聚体疫苗方法的发展,即来自几种抗原的多个(通常为8-10个氨基酸长)αβ CD8+ 细胞毒性T淋巴细胞表位被连接成单个人工构建体。这种多聚体构建体可以使用多种不同的疫苗载体方式递送,构建体中的每个表位都具有单独的免疫原性。